Is there a Place for LDL-apheresis in Non-Homozygous Patients?

Wood D. , De Backer G. , Faergeman O. , Graham I. , Mancia G. , Pyörälä K. . Prevention of coronary heart diseases in clinical practice. Recommendations of the second joint task force of European and other societies on coronary prevention. Eur Heart J 1998; 19: 1434–503.

Shepherd J. , Cobbe S.M. , Ford I. . Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia. West of Scotland Coronary Prevention Study Group [see comments]. N Engl J Med 1995; 333: 1301–7.

Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S). Lancet 1994; 344: 1383–9.

Sacks F.M. , Pfeffer M.A. , Moye L.A. . The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels. Cholesterol and Recurrent Events Trial investigators. N Engl J Med 1996; 335: 1001–9.

Keys A. . Seven countries: a multivariate analysis of death and coronary heart disease. Harvard University Press., 1980.

Sacks F.M. , Moye L.A. , Davis B.R. . Relationship between plasma LDL concentrations during treatment with pravastatin and recurrent coronary events in the Cholesterol and Recurrent Events trial. Circulation 1998; 97: 1446–52.

Anderson K.M. , Castelli W.P. , Levy D. . Cholesterol and mortality: 30 years of follow-up from the Framingham study. JAMA 1987; 257: 2176–80.

Neaton J.D. , Blackburn H. , Jacobs D. . Serum cholesterol level and mortality findings for men screened in the Multiple Risk Factor Intervention Trial. Multiple Risk Factor Intervention Trial Research Group Arch Intern Med 1992; 152: 1490–500.

Assmann G. , Cullen P. , Schulte H. . The Munster Heart Study (PROCAM) -Results of follow-up at 8 years. Eur Heart J 1998; 19: A2–A1 I.

Waidner T. , Franzen D. , Voelker W. . The effect of LDL apheresis on progression of coronary artery disease in patients with familial hyper-cholesterolemia. Results of a multicenter LDL apheresis study. Clin Invest 1994; 72: 858–63.

Schuff-Werner P. , Gohlke H. , Bartmann U. . The HELP-LDL-apheresis multicentre study, an angiographically assessed trial on the role of LDLapheresis in the secondary prevention of coronary heart disease. II Final evaluation of the effect of regular treatment on LDL-cholesterol plasma concentrations and the course of coronary heart disease. Eur J Clin Invest 1994; 24: 724–32.

Kroon A.A. , Aengevaeren W.R.M. , van der Werf T. . LDLapheresis atherosclerosis regression study (LAARS). Effect of aggressive versus conventional lipid lowering treatment on coronary atherosclerosis. Circulation 1996; 93: 1826–35.

Mabuchi H. , Koizumi J. , Shimizu M. , Kajinami K. , Miyamoto S. , Ueda K. , Takegoshi T. for the Hokuriku-FH-LDL-Apheresis Study Group. Long-term efficacy of low-density lipoprotein apheresis on coronary heart disease in familial hypercholesterolemia. Am J Cardiol 1998; 82: 1489–95.

Thompson G.R. , Maher V.M.G. , Matthews S. . Familial hypercholesterolaemia regression study: a randomised trial of low density-lipoprotein apheresis. Lancet 1995; 345: 811–6.

Gordon B. , Kelsey S. , Dau P. . Long-term effects of low-density lipoprotein apheresis using an automated dextran sulfate cellulose adsorption system. Am J Cardiol 1998; 81: 407–11.

Summary of the second report of the National Cholesterol Education Program (NCEP) expert panel on detection, evaluation, and treatment of high blood cholesterol in adults. JAMA 1993; 269(23): 3015–23.

Serruys P.W. , van Hout B. , Bonnier H. . Randomised comparison of implantation of heparin-coated stents with balloon angioplasty in selected patients with coronary artery disease (Benestent II). Lancet 1998; 352: 673–81.